TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Minocycline in the Treatment of Angelman Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The participant is between the ages of 4 to 12 years old.~2. The participant has been previously diagnosed with AS by clinical evaluation.~3. The participant's diagnosis has molecular confirmation (e.g. karyotyping, fluorescent in situ hybridization (FISH), DNA methylation test or sequencing of the ubiquitin-protein ligase E3A gene) of the diagnosis.~4. The participant has a CGI-Severity Score of at least 4 indicating a moderate level of behavioral difficulty.~5. The participant is male or female.~6. The participant has an acceptable surrogate capable of giving consent on the participant's behalf.~Exclusion Criteria:~1. The participant was diagnosed with AS with no identifiable molecular abnormality.~2. The participant has a known allergy to MC or tetracycline.~3. The participant is currently enrolled in a study in which a drug, vitamin or dietary manipulation is used in the treatment of AS.~4. The participant suffers from severe or uncontrolled seizures or any other medical condition rendering the patient unstable.~5. The participant suffers from cardiovascular, respiratory, liver, kidney or hematologic disease.~6. The participant suffers from liver disease or elevated liver function tests.~7. The participant has a history of neutropenia, anemia or thrombocytopenia.~8. The participant has a history of systemic lupus erythematosus or an anti-nuclear antibody (ANA) titer or \>1:40.~9. The participant is pregnant or at risk of becoming pregnant (sexually active females).~10. The participant experiences persistent psychotic symptoms.~11. The participant (or a parent/caregiver) is not willing to participate in clinic visits.~12. The participant experiences severe symptoms judged to likely to endanger the participant's safety or the safety of others.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Children with Angelman Syndrome (Type: EXPERIMENTAL): Children with a molecularly confirmed diagnosis of Angelman Syndrome meeting the protocol requirements will be selected randomly. All participants will receive the study drug, minocycline, over an identical time course. Participants will undergo identical baseline, 8 and 16 week follow up assessments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Clinical Outcomes of the REALIZE Adjustable Gastric Band-C

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Received an implant with the Realize Band-C according to the following indications for use:~   1. Body Mass Index (BMI) of at least 40 kg/m2, or a BMI of at least 35 kg/m2 with one or more co-morbid conditions.~  2. Male and female adult patients (adult is defined as 18 years of age or older)~  3. Failed more conservative weight-reduction alternatives, such as supervised diet, exercise, and behavior modification programs.~2. Able to comprehend, follow, and give signed informed consent.~Exclusion Criteria:~1. Inflammatory diseases of the gastrointestinal tract, including severe intractable esophagitis, gastric ulceration or duodenal ulceration, or specific inflammation such as Crohn's disease;~2. Severe cardiopulmonary disease or other serious organic disease;~3. Upper gastrointestinal bleeding conditions such as esophageal or gastric varices or intestinal telangiectases;~4. Portal hypertension;~5. Anomalies of the gastrointestinal tract such as atresia or stenosis;~6. Cirrhosis of the liver;~7. Chronic pancreatitis;~8. Localized or systemic infection;~9. On chronic, long-term systemic steroid treatment or systemic steroids within 15 days of surgery;~10. Unable or unwilling to comply with dietary restrictions required by this procedure;~11. Known allergy to materials contained in the gastric band or its Injection Port;~12. Women who are pregnant;~13. Women at childbearing potential planning to get pregnant within 2 years or not using acceptable methods of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient may be transplanted with stem cells from any source using either a myeloablative or nonmyeloablative preparative regimen~* Patient may be any age~* Patient must have biopsy proven new onset of aGVHD; Clinical Grading must be II-IV and may occur after stem cell transplant or donor leukocyte infusion (DLI). Patients may begin Etanercept treatment prior to biopsy confirmation of GVHD. Acute GVHD will be determined by clinical presentation and not timing from stem cell infusion~* Patient must be on solumedrol at a dose of 2mg/kg/day of actual body weight for no more than 72 hours prior to the initiation of etanercept~* Patient must have evidence of neutrophil engraftment with an ANC of \> 500 for three consecutive days~* Pulse ox \> 90% on room air~Exclusion Criteria:~* Pregnancy or nursing mother~* Intolerance or allergic reaction to etanercept~* Previous use of steroids for treatment of acute GVHD~* Active infection, chronic or localized, not responding to antibiotics, with continued signs of infection (patients with a positive C. Difficile test will not be excluded from the study)~* Condition that might predispose to developing serious infections (i.e. active and uncontrolled diabetes mellitus, sickle cell anemia)~* Other investigational agents for the treatment or prophylaxis of graft-vs-host disease within the past 2 weeks~* Serum creatinine \> 2.0mg/dl~* Patients being treated for acute pulmonary dysfunction (IPS) study using etanercept~* Patients with hypotension believed to be secondary to sepsis syndrome or heart failure requiring \> 1 inotropic agent, or dopamine \>5mcg/kg/minute for blood pressure support~* Evidence of congestive heart failure on clinical exam~* Evidence of hepatic dysfunction with an ALT or AST \> 2.5 x ULN, not due to GVHD

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): etanercept treatment for GVHD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have a diagnosis of T2DM and be currently treated with metformin~* Patients in the study must have a HbA1c between \>=7 and \<=10.5%~* Patients must have a fasting plasma glucose (FPG) \<270 mg/dL (15 mmol/L)~Exclusion Criteria:~* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, diabetes secondary to pancreatitis or pancreatectomy, or a severe hypoglycemic episode within 6 months before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 50 mg bid (Type: EXPERIMENTAL): Each patient will receive 50 mg canagliflozin twice daily for 18 weeks.
- Canagliflozin 150 mg bid (Type: EXPERIMENTAL): Each patient will receive 150 mg canagliflozin twice daily for 18 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive matching placebo twice daily for 18 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Misoprostol for Small Bowel Ulcers and Obscure Bleeding Due to Aspirin or Nonsteroidal Antiinflammatory Drugs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~Obscure occult gastrointestinal bleeding: presence of one or more of the following:~* Positive fecal occult blood test within last 3 months~* Iron deficiency anemia (ferritin \<100 ug/l, hemoglobin \[Hb\] 7-12 g/dl \[female\] or 7-13 g/dl \[male\])~* Drop in haemoglobin, \> 2gm/dl from baseline, in the absence of potential or actively bleeding lesion detectable on upper endoscopy or colonoscopy.~Normal/ absence of potentially bleeding lesions on full upper endoscopy and colonoscopy.~Taking low-dose aspirin (75-325m/ day) and/ or NSAIDs~MAIN EXCLUSION CRITERIA:~* Incomplete upper endoscopy or colonoscopy~* Systemic disease that is unstable at the time of randomisation (unstable vital signs; ongoing non-gastrointestinal investigations; frequent modifications to treatment)~* Intake of certain drugs: high-dose steroids (\>7.5-mg prednisolone/ day), cytotoxic drugs, or warfarin.~* Upper gastrointestinal lesions: oesophageal varices; oesophageal stricture; oesophageal or gastric neoplasms; pyloric stenosis; peptic ulcers; vascular malformations.~* Colonic disorders: neoplasms or adenomatous polyps; inflammatory bowel disease; vascular malformations; actively bleeding diverticular disease~* Women planning pregnancy, pregnant or women of child-bearing potential not using two contraceptive methods, one of which must be highly effective \[implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomised partner\]~* Hypotension: systolic blood pressure \<100-mm Hg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Misoprostol (Type: ACTIVE_COMPARATOR): Misoprostol
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation~* Healthy males and females according to the following criteria:~Based upon a complete medical history, including physical examination, vital signs (BP, PR), 12-lead ECG and clinical laboratory tests (haematology, clinical chemistry and urinalysis).~* Age 18 to 45 years (incl.)~* Body mass index by Quetelet between 18.50 to 24.99 kg/m2 (incl.)~* Female subjects of childbearing potential who agree on using double-barrier contraception during the study. If a female is postmenopausal (no menses for at least 2 years) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) she will be exempt from the requirement. In case of using oral contraceptives, these should be withdrawn at least 2 months before the first drug dosing.~* Male subjects who agree on using effective contraception during the study (barrier contraceptive methods)~Exclusion criteria:~* Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance~* Any laboratory value outside the reference range that is of clinical relevance~* Any evidence of a clinically relevant concomitant disease~* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders~* Positive results of blood tests for infections (HIV, syphilis, hepatitis B or C)~* A positive urine drug screening test at screening and on admission to the trial site in each treatment period.~* A positive alcohol breath test at screening and on admission to the trial site in each treatment period.~* Surgery of the gastrointestinal tract (except appendectomy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Fixed dose combination (Type: EXPERIMENTAL): Linagliptin/Metformin
- Free combination (Type: EXPERIMENTAL): Linagliptin and Metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adequate bone-marrow reserve (ie, white-blood-cell count ≥4000 x106 cells/L and platelet count ≥120 x 109/L)~* normal renal function (ie, serum creatinine ≤123•76 μmol/L)~* normal liver function (ie, serum glutamic-oxaloacetic transaminase ≤42 U/L, serum glutamic-pyruvic transaminase ≤48 U/L, and total bilirubin ≤22•23 μmol/L)~* Karnofsky performance status between 50 and 100.~Exclusion Criteria:~* previous treatment with BCG or electromotive mitomycin~* treatment with any other intravesical cytostatic agent within the past 6 months~* concomitant urothelial tumours of the upper urinary tract;~* previous muscle-invasive (ie, stage T2 or higher) transitional-cell - carcinoma of the bladder~* bladder capacity less than 2 L~* untreated urinary-tract infection~* severe systemic infection (ie, sepsis)~* urethral strictures that would prevent endoscopic procedures and repeated catheterisation~* disease of upper urinary tract (eg, vesicoureteral reflux or urinary-tract stones) that would make multiple transurethral procedures a risk~* previous radiotherapy to the pelvis~* other concurrent chemotherapy~* treatment with radiotherapy-response or biological-response modifiers;~* history of tuberculosis~* other malignant diseases within 5 years of trial registration (except for basal-cell carcinoma)~* pregnancy or nursing~* psychological, familial, sociological, or geographical factors that would preclude study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Intravesical BCG alone (Type: ACTIVE_COMPARATOR): None
- Intravesical sequential BCG and EMDA MMC (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥18 years~* HIV-2 mono infection, confirmed by ELISA and Western Blot test or Immunoblot,~* antiretroviral treatment-naive, whatever the duration and indication of prior treatments,~* indication to treatment, with at least one of the following criteria : type B or C events, CD4 lymphocytes count below 500/mm3 at screening-visit or CD4 lymphocytes count decrease of at least 50 cell/µL/year over the last 3 years with the last CD4 lymphocytes count within -/+ 10 % of the nadir, plasma HIV-2 RNA load over or equal to 100 copies/mL at screening-visit,~* Pneumocystis prophylaxis if CD4 lymphocytes count below 200/mm3, combined to a toxoplasmosis prophylaxis in case of a positive toxoplasmosis serology,~* French residency for at least one year,~* Written informed consent, signed by the participant and the investigator (at the latest on the screening-visit and prior any study related intervention)~* Affiliate or beneficiary of a social security system (State Medical Assistance is not a social security scheme).~Exclusion Criteria:~* Absence of effective contraception method(women),~* Pregnancy, breastfeeding or wish for pregnancy during the trial,~* Curative treatment of a progressive opportunistic infection not compatible with those evaluated in the present study,~* Malignant or tumorous affection requiring chemotherapy or radiotherapy,~* Decompensated cirrhosis,~* Viral hepatitis C with a Metavir score over F2,~* Hemoglobinemia below 7g/dL, polynuclear neutrophils below 500/mm3, platelets below 50 000/mm3, creatinine clearance below 50 mL/mn, transaminase, alkaline phosphatase or bilirubin over 2.5N,~* Contraindication to one of the excipients of study treatments,~* Insuline-dependent diabetes mellitus not well controlled (with glycated haemoglobin (HbA1C) over 7%),~* Long-term corticosteroid treatment (more than 3 weeks of treatment),~* Judicial protection, legal guardianship,~* Participation in other therapeutic trial or comprising an exclusion period ongoing at the time of the screening-visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- raltegravir / emtricitabine / tenofovir disoproxil fumarate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients with STEMI undergoing primary PPCI~* Age \> 18 years old~Exclusion criteria:~* Inability to provide written informed consent~* Known history of prior intracranial bleeding~* On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in the prior 10 days~* Known allergies to aspirin, ticagrelor or cangrelor~* On treatment with oral anticoagulant~* Treatment with glycoprotein IIb/IIIa inhibitors~* Fibrinolytics within 24 hours~* Active bleeding~* High risk of bleeding~* Known platelet count \<80x106/mL~* Known hemoglobin \<10 g/dL~* Intubated patients (prior to randomization)~* Known creatinine clearance \<30 mL/minute or on hemodialysis.~* Known severe hepatic dysfunction~* Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection~* Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.~* Pregnant or lactating females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cangrelor (Type: EXPERIMENTAL): Cangrelor will be administered as 30 μg/kg bolus followed by 4 μg/kg/min infusion for 2 hours
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline bolus and infusion for 2 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between the Effects of High Doses Statin on Ventricular Remodeling in STEMI Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Electrocardiogram showed abnormal elevation of the ST segment.~2. First myocardial infarction occurred.~3. The patients received one-stage percutaneous coronary intervention (PCI) therapy within 12 h.~Exclusion Criteria:~1. Severe cardiac insufficiency.~2. Hepatic insufficiency (continuous increase of serum transaminase more than 3 times of the upper limit of normal level).~3. Renal insufficiency (creatinine clearance rate \<30 mL/min).~4. Addition of others blood lipid lowering and antioxidant drugs during follow up period.~5. Familial hypercholesterolemia.~6. Malignant tumor.~7. Immune system disease.~8. Acute infectious disease.~9. Hypersensitivity to rosuvastatin and Atorvastatin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin group (Type: EXPERIMENTAL): patients will receive Rosuvastatin orally (20 mg) at night once daily
- Atorvastatin group (Type: EXPERIMENTAL): patients will receive Atorvastatin orally (40 mg) at night once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete